title: Cancer cells differentially activate and thrive on de novo lipid synthesis pathways in a low-lipid environment.
abstract: Increased lipogenesis is a hallmark of a wide variety of cancers and is under intense investigation as potential antineoplastic target. Although brisk lipogenesis is observed in the presence of exogenous lipids, evidence is mounting that these lipids may adversely affect the efficacy of inhibitors of lipogenic pathways. Therefore, to fully exploit the therapeutic potential of lipid synthesis inhibitors, a better understanding of the interrelationship between de novo lipid synthesis and exogenous lipids and their respective role in cancer cell proliferation and therapeutic response to lipogenesis inhibitors is of critical importance. Here, we show that the proliferation of various cancer cell lines (PC3M, HepG2, HOP62 and T24) is attenuated when cultured in lipid-reduced conditions in a cell line-dependent manner, with PC3M being the least affected. Interestingly, all cell lines--lipogenic (PC3M, HepG2, HOP62) as well as non-lipogenic (T24)--raised their lipogenic activity in these conditions, albeit to a different degree. Cells that attained the highest lipogenic activity under these conditions were best able to cope with lipid reduction in term of proliferative capacity. Supplementation of the medium with very low density lipoproteins, free fatty acids and cholesterol reversed this activation, indicating that the mere lack of lipids is sufficient to activate de novo lipogenesis in cancer cells. Consequently, cancer cells grown in lipid-reduced conditions became more dependent on de novo lipid synthesis pathways and were more sensitive to inhibitors of lipogenic pathways, like Soraphen A and Simvastatin. Collectively, these data indicate that limitation of access to exogenous lipids, as may occur in intact tumors, activates de novo lipogenesis is cancer cells, helps them to thrive under these conditions and makes them more vulnerable to lipogenesis inhibitors. These observations have important implications for the design of new antineoplastic strategies targeting the cancer cell's lipid metabolism.
authors.affiliation: KU Leuven - University of Leuven, Faculty of Medicine, Department of Oncology, Laboratory of Lipid Metabolism and Cancer, Leuven, Belgium.
authors.forename: Veerle W
authors.initials: VW
authors.lastname: Daniëls
authors.affiliation: Department of Oncology, Janssen Research and Development, a division of Janssen Pharmaceutica NV, Beerse, Belgium.
authors.forename: Karine
authors.initials: K
authors.lastname: Smans
authors.affiliation: Department of Oncology, Janssen Research and Development, a division of Janssen Pharmaceutica NV, Beerse, Belgium.
authors.forename: Ines
authors.initials: I
authors.lastname: Royaux
authors.affiliation: Department of Oncology, Janssen Research and Development, a division of Janssen Pharmaceutica NV, Beerse, Belgium.
authors.forename: Melanie
authors.initials: M
authors.lastname: Chypre
authors.affiliation: KU Leuven - University of Leuven, Faculty of Medicine, Department of Oncology, Laboratory of Lipid Metabolism and Cancer, Leuven, Belgium.
authors.forename: Johannes V
authors.initials: JV
authors.lastname: Swinnen
authors.affiliation: KU Leuven - University of Leuven, Faculty of Medicine, Department of Oncology, Laboratory of Lipid Metabolism and Cancer, Leuven, Belgium; Department of Oncology, Janssen Research and Development, a division of Janssen Pharmaceutica NV, Beerse, Belgium; Microbiology and Molecular Genetics, University of the Punjab, Lahore, Pakistan.
authors.forename: Nousheen
authors.initials: N
authors.lastname: Zaidi
mesh_terms: D053898:Biosynthetic Pathways / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002784:Cholesterol / Q000378:metabolism; D005227:Fatty Acids / Q000378:metabolism; D006801:Humans; D050356:Lipid Metabolism / Q000187:drug effects; D008055:Lipids / Q000096:biosynthesis* / Q000494:pharmacology; D008079:Lipoproteins, VLDL / Q000378:metabolism; D009369:Neoplasms / Q000378:metabolism* / Q000473:pathology*; D015854:Up-Regulation / Q000187:drug effects
chemical_list: D005227:Fatty Acids; D008055:Lipids; D008079:Lipoproteins, VLDL; D002784:Cholesterol